Abstract:Accumulating evidence suggests that spinal cord astrocytes play an important role in neuropathic pain sensitization by releasing astrocytic mediators (e.g. cytokines, chemokines and growth factors). However, it remains unclear how astrocytes control the release of astrocytic mediators and sustain late-phase neuropathic pain. Astrocytic connexin-43 (now known as GJ1) has been implicated in gap junction and hemichannel communication of cytosolic contents through the glial syncytia and to the extracellular space, respectively. Connexin-43 also plays an essential role in facilitating the development of neuropathic pain, yet the mechanism for this contribution remains unknown. In this study, we investigated whether nerve injury could upregulate connexin-43 to sustain late-phase neuropathic pain by releasing chemokine from spinal astrocytes. Chronic constriction injury elicited a persistent upregulation of connexin-43 in spinal astrocytes for >3 weeks. Spinal (intrathecal) injection of carbenoxolone (a non-selective hemichannel blocker) and selective connexin-43 blockers (connexin-43 mimetic peptides (43)Gap26 and (37,43)Gap27), as well as astroglial toxin but not microglial inhibitors, given 3 weeks after nerve injury, effectively reduced mechanical allodynia, a cardinal feature of late-phase neuropathic pain. In cultured astrocytes, TNF-α elicited marked release of the chemokine CXCL1, and the release was blocked by carbenoxolone, Gap26/Gap27, and connexin-43 small interfering RNA. TNF-α also increased connexin-43 expression and hemichannel activity, but not gap junction communication in astrocyte cultures prepared from cortices and spinal cords. Spinal injection of TNF-α-activated astrocytes was sufficient to induce persistent mechanical allodynia, and this allodynia was suppressed by CXCL1 neutralization, CXCL1 receptor (CXCR2) antagonist, and pretreatment of astrocytes with connexin-43 small interfering RNA. Furthermore, nerve injury persistently increased excitatory synaptic transmission (spontaneous excitatory postsynaptic currents) in spinal lamina IIo nociceptive synapses in the late phase, and this increase was suppressed by carbenoxolone and Gap27, and recapitulated by CXCL1. Together, our findings demonstrate a novel mechanism of astrocytic connexin-43 to enhance spinal cord synaptic transmission and maintain neuropathic pain in the late-phase via releasing chemokines.

Connexins as therapeutic targets in neurological and neuropsychiatric disorders

Connexin Hemichannels in Astrocytes: Role in CNS Disorders

[Gap Junction and Function of Brain].

Antidepressants Impact Connexin 43 Channel Functions in Astrocytes

Gap junctions and hemichannels composed of connexins: potential therapeutic targets for neurodegenerative diseases

Function of Connexins in the Interaction between Glial and Vascular Cells in the Central Nervous System and Related Neurological Diseases

Role of Connexins 30, 36, and 43 in Brain Tumors, Neurodegenerative Diseases, and Neuroprotection

Astroglial connexins and cognition: memory formation or deterioration?

Astroglial Connexin43 as a Potential Target for a Mood Stabiliser

Astroglial Connexin43 Hemichannels Tune Basal Excitatory Synaptic Transmission

The function of astrocytes and their role in neurological diseases

Astrocyte-restricted disruption of connexin-43 impairs neuronal plasticity in mouse barrel cortex.

[Gap junctions: A new therapeutic target in major depressive disorder?]

Connexin-43 Induces Chemokine Release from Spinal Cord Astrocytes to Maintain Late-Phase Neuropathic Pain in Mice

Astrocytes in human central nervous system diseases: a frontier for new therapies

Connexin 43, a new therapeutic target for cardiovascular diseases

Astroglial connexin 43 is a novel therapeutic target for chronic multiple sclerosis model

Upregulation of astroglial connexin 30 impairs hippocampal synaptic activity and recognition memory

New insights into the expression and function of neural connexins with transgenic mouse mutants

Function and therapeutic value of astrocytes in neurological diseases

Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection